Healthcare technology company Zenosense (OTC: ZENO), through its joint venture ownership of MIDS Medical Limited (“MML”), is developing “MIDS”, a nano-magnetic detection technology to allow true laboratory accuracy at the point-of-care (“POC”). A recent article discussing the company reads: “Zenosense, through MML, intends to develop wider applications of its MIDS technology platform to include POC immunoassay testing of many other medical conditions and diseases. MML’s test results on its Hybrid Strip development system already indicate that MML can detect commercially available assay beads at extremely low levels. The successful incorporation of magnetic detection should provide a significant improvement in accuracy over existing POC devices that are limited to imperfect optical detection, which cannot equal laboratory analyzer performance. … The system uniquely positions Zenosense to capitalize on a fast-growing market. According to Grand View Research, the global cardiac biomarkers market is expected to reach $13.3 billion by 2024, and Markets and Markets report that the global immunoassay testing market is projected to be worth $25.45 billion by 2021.”
To view the full article, visit http://nnw.fm/2fgYF
About Zenosense, Inc.
Zenosense Inc.’s primary focus, through its joint venture ownership in MIDS Medical Ltd., is the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac™. Zenosense Inc. is also the holder of an exclusive global license agreement to develop and market effective medical devices for use in hospitals and primary healthcare settings targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. For more information, visit the company’s website at www.ZenoSense.com.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com